How could formoterol reverse fatty liver?

Asthma drug formoterol enters trials for fatty liver

An asthma medication called formoterol is being spotlighted as a possible treatment for a type of fatty liver disease linked to metabolic dysfunction, described in the coverage as MASH-related liver damage.

The scientific rationale comes from a two-step evidentiary path. First, results from mice suggested that formoterol could reverse damaging changes in the liver. Second, there is supporting signal from observational studies in humans, which looked at associations related to the disease and potential pathways that formoterol might influence. Together, these findings have prompted researchers to plan or initiate new clinical trials.

Why this matters is that MASH (often discussed alongside nonalcoholic steatohepatitis) represents a major clinical challenge: it can progress from fat buildup to liver inflammation and scarring, increasing the risk of serious liver outcomes. Existing treatments are still limited, and patients need therapies that can meaningfully improve liver pathology.

Formoterol belongs to a class of drugs known for targeting airway receptors, but the research suggests it may also affect processes relevant to liver disease—at least in preclinical models and in patterns seen in people. The next step, clinical trials, will be crucial for determining whether the effect seen in animals translates into measurable benefits in patients and whether any side effects are acceptable in a population that may not otherwise require asthma medications.

Key outcome measures in such trials typically include liver fat reduction and markers of inflammation and fibrosis, along with safety monitoring, because a drug’s benefits must outweigh potential risks.

If the trials show that formoterol can improve MASH safely, it would be notable for repurposing an existing drug and potentially accelerating the path to therapy for a condition with few established options.